glp-1 masld Direct and indirect effects of GLP1‐RA in obesity, T2D and Emerging Role of GLP-1 Receptor

Approximately 20%-30% of individuals with MASLD progress to MASH, characterized by hepatocyte ballooning, lobular inflammation, and variable fibrosis, and 10%-20% of MASH patients develop advanced fibrosis (stages F3-F4) or cirrhosis over their lifetime [6,13]

Tirzepatide Tirzepatide is a dual GLP-1/GIP receptor agonist

The SUMMIT study assesses tirzepatides impact on HF with HFpEF in obese patients

In addition to their established benefits for the management of diabetes and obesity, GLP-1RAs have shown potential in managing MASLD through mechanisms such as reducing hepatic lipogenesis, improving insulin sensitivity, and modulating inflammation

PubMed Urva S, Coskun T, Loh MT, et al

Do this first thing in the morning or before attempting a bowel movement